Adjuvant transarterial chemoembolization following radical resection for intrahepatic cholangiocarcinoma: A multi-center retrospective study
Lei Wang, Zi-Guo Lin, Qiao Ke, Jian-Ying Lou, Shu-Guo Zheng, Xin-Yu Bi, Jian Ming Wang, Wei Guo, Fu‐Yu Li, Jian Wang, Ya-Min Zheng, Jing-Dong Li, Shi Cheng, Wei-Ping Zhou, Yong-Yi Zeng · Journal of Cancer · 2020
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2020
Abstract
Background and Aims:The prognosis of intrahepatic cholangiocarcinoma (ICC) after radical resection is far from satisfactory, but the effect of postoperative transarterial chemoembolization (p-TACE) remains controversial.This multi-center retrospective study was to evaluate the clinical value of p-TACE and identify the selected patients who would benefit from p-TACE.Methods: Data of ICC patients who underwent radical resection with/without p-TACE therapy was obtained from 12 hepatobiliary centers in China between Jan 2014 and Jan 2017.Overall survival (OS) was set as the primary endpoint, which was analyzed by the Kaplan-Meier method before and after propensity score matching (PSM).Subgroup analysis was conducted based on the established staging system and survival risk stratification.Results: A total of 335 patients were enrolled in this study, including 39 patients in the p-TACE group and 296 patients in the non-TACE group.Median OS in the p-TACE group was longer than that in the non-TACE group (63.0 months vs.
18.0 months, P=0.041), which was confirmed after 1:1 PSM (P=0.009).According to the 8 th TNM staging system, patients with stage II and stage III stage would be benefited from p-TACE (P=0.021).Subgroup analysis stratified by risk factors showed that p-TACE could only benefit patients with risk factors <2 (P=0.027).Conclusion: Patients with ICC should be recommended to receive p-TACE following radical resection, especially for those with stage II, stage III or risk factors <2.However, the conclusion deserved further validation.
Open the resolved locator · 10.7150/jca.40358
Metadata licence: OpenAlex metadata (CC0)